Trials / Completed
CompletedNCT00830128
A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin In Patients With Fibromyalgia
An Open-Label Extension Safety And Efficacy Study Of Pregabalin (CI-1008) For The Treatment Of Fibromyalgia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 106 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the safety and efficacy of the long-term use of pregabalin at doses up to 450 mg/day in patients with fibromyalgia who have completed 16 weeks of dosing in Study A0081208 (NCT00830167).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pregabalin (Lyrica) | Dosage: 300-450 mg/day (150-225 mg twice daily), oral administration, Treatment duration: 52 weeks |
Timeline
- Start date
- 2009-07-01
- Primary completion
- 2011-02-01
- Completion
- 2011-02-01
- First posted
- 2009-01-27
- Last updated
- 2021-01-25
- Results posted
- 2012-02-14
Locations
19 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00830128. Inclusion in this directory is not an endorsement.